LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Postsynaptic Density Genes Linked to Multitude of Brain Disorders

By LabMedica International staff writers
Posted on 29 Dec 2010
The postsynaptic density (PSD), an enigmatic structure located in some brain cell synapses, was analyzed at the proteomic and genomic levels and found to be the source of proteins involved in more than 130 brain diseases.

The PSD is a physical feature of the cytoskeleton found in some synapses of brain cells. PSDs were originally identified by electron microscopy as an electron-dense region at the membrane of a postsynaptic neuron. A PSD's molecular scaffolding is usually composed of L-glutamate neurotransmitter receptors. PSDs also contain cell adhesion molecules and a diverse set of other signaling proteins. PSDs vary in size and composition among brain regions, varying in size from about 250 nm to 500 nm in diameter and 25 nm to 50 nm in thickness, depending on the activity state of the synapse.

In the current study, investigators at the Wellcome Trust Sanger Institute (Hinxton, United Kingdom) isolated the postsynaptic density from human neocortex (hPSD) from patients undergoing brain surgery. The material was examined at both the genomic and proteomic levels. Results published in the December 19, 2010, online edition of the journal Nature Neuroscience revealed that the investigators had identified 1,461 distinct proteins. Mutations among the genes coding for these proteins were linked to 133 neurological and psychiatric diseases.

"We found over 130 brain diseases involve the PSD -- far more than expected," said senior author Dr. Seth Grant, a principle investigator at the Wellcome Trust Sanger Institute. "The human PSD is at center stage of a large range of human diseases affecting millions of people. The conservation of the structure of these proteins suggests that the behaviors governed by the PSD and the diseases associated with them have not changed much over many millions of years."

"We can also see ways to develop new genetic diagnostic tests and help doctors classify the brain diseases," said Dr. Grant.

In an effort to boost PSD research, the investigators have created and released into the public domain a "molecular roadmap" for human synapses showing how the 1,461 proteins and the 130 diseases interconnect.

Related Links:
Wellcome Trust Sanger Institute


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Automatic CLIA Analyzer
Shine i9000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more